Dynamic Marketing consultant Answers LLC raised its holdings in stocks of Novo Nordisk A/S (NYSE:NVO – Unfastened Record) via 112.2% all over the 3rd quarter, HoldingsChannel.com stories. The company owned 29,323 stocks of the corporate’s inventory after purchasing an extra 15,504 stocks all over the length. Dynamic Marketing consultant Answers LLC’s holdings in Novo Nordisk A/S had been value $2,667,000 as of its most up-to-date SEC submitting.

Different massive traders have additionally made adjustments to their positions within the corporate. Ritter Daniher Monetary Advisory LLC DE received a brand new place in stocks of Novo Nordisk A/S all over the primary quarter value $28,000. Stone Space Funding Control LLC greater its place in stocks of Novo Nordisk A/S via 55.3% all over the second one quarter. Stone Space Funding Control LLC now owns 177 stocks of the corporate’s inventory value $29,000 after buying an extra 63 stocks within the ultimate quarter. Cornerstone Making plans Workforce LLC received a brand new place in stocks of Novo Nordisk A/S all over the second one quarter value $29,000. Lee Monetary Co received a brand new place in stocks of Novo Nordisk A/S all over the second one quarter value $32,000. In any case, Tower Analysis Capital LLC TRC greater its place in stocks of Novo Nordisk A/S via 165.3% all over the primary quarter. Tower Analysis Capital LLC TRC now owns 199 stocks of the corporate’s inventory value $32,000 after buying an extra 124 stocks within the ultimate quarter. 6.41% of the inventory is owned via institutional traders and hedge price range.

Novo Nordisk A/S Value Efficiency

NYSE:NVO opened at $101.31 on Thursday. Novo Nordisk A/S has a 12 months low of $65.05 and a 12 months top of $105.69. The corporate has a debt-to-equity ratio of 0.21, a snappy ratio of 0.65 and a present ratio of 0.82. The company has a marketplace cap of $454.63 billion, a price-to-earnings ratio of 42.04, a PEG ratio of one.37 and a beta of 0.40. The company’s fifty day transferring moderate is $99.59 and its two-hundred day transferring moderate is $67.77.

Novo Nordisk A/S (NYSE:NVO – Get Unfastened Record) ultimate posted its quarterly income effects on Thursday, November second. The corporate reported $0.73 EPS for the quarter, beating the consensus estimate of $0.69 via $0.04. Novo Nordisk A/S had a web margin of 35.20% and a go back on fairness of 86.53%. The corporate had earnings of $8.58 billion for the quarter. Analysis analysts be expecting that Novo Nordisk A/S will put up 2.61 EPS for the present yr.

Wall Boulevard Analyst Weigh In

Various equities analysts have not too long ago issued stories on NVO stocks. StockNews.com raised Novo Nordisk A/S from a “purchase” score to a “strong-buy” score in a analysis file on Monday, October sixteenth. TD Cowen upped their goal fee on Novo Nordisk A/S from $105.00 to $115.00 and gave the corporate an “outperform” score in a analysis file on Monday, December 4th. Argus assumed protection on Novo Nordisk A/S in a analysis file on Monday, October second. They issued a “purchase” score and a $110.00 goal fee at the inventory. In any case, Cantor Fitzgerald began protection on Novo Nordisk A/S in a analysis file on Friday, December 1st. They issued an “obese” score and a $120.00 goal fee at the inventory. One analysis analyst has rated the inventory with a hang score, 5 have issued a purchase score and one has issued a powerful purchase score to the inventory. In keeping with knowledge from MarketBeat, the inventory lately has a consensus score of “Purchase” and a consensus goal fee of $115.00.

View Our Newest Inventory Research on Novo Nordisk A/S

About Novo Nordisk A/S

(Unfastened Record)

Novo Nordisk A/S, a healthcare corporate, engages within the analysis, construction, manufacture, and advertising of pharmaceutical merchandise international. It operates in two segments, Diabetes and Weight problems care, and Uncommon Illness. The Diabetes and Weight problems care phase supplies merchandise within the spaces of insulins, GLP-1 and similar supply methods, oral antidiabetic merchandise, weight problems, glucagon, needles, and different continual illnesses.

See Additionally

Wish to see what different hedge price range are maintaining NVO? Discuss with HoldingsChannel.com to get the newest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Unfastened Record).

Obtain Information & Rankings for Novo Nordisk A/S Day-to-day – Input your e-mail deal with beneath to obtain a concise day-to-day abstract of the newest information and analysts’ scores for Novo Nordisk A/S and similar firms with MarketBeat.com’s FREE day-to-day e-mail e-newsletter.